Skip to main content

ebglyss

Generic: lebrikizumab·Brand: Ebglyss

ebglyss: sourced relationships with 1 company · 1 FDA decision.

ebglyss evidence translation

What we can confirm

What it means

Source-backed records connect ebglyss to LLY; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could ebglyss → LLY affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

For the treatment of adult and adolescent patients 12 years or older with moderate to severe atopic dermatitis (in Europe, in collaboration with Almirall S.A.).

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
ELI LILLY & Co (LLY)
licensee · Reported 2025-02-19 · Current development: unknownSource
For the treatment of adult and adolescent patients 12 years …
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE EBGLYSS is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids. EBGLYSS ® is an interleukin-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids. ( 1 )(LLY)FDA ↗
BLA761306Type 1 - New Molecular EntityStandardOtherInjectable

Frequently asked questions

Which companies have sourced relationships with ebglyss?

ebglyss has dated SEC/FDA relationship records for ELI LILLY & Co.

What is ebglyss's latest FDA decision?

The most recent tracked FDA decision for ebglyss is Approval for 1 INDICATIONS AND USAGE EBGLYSS is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids. EBGLYSS ® is an interleukin-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids. ( 1 ), dated September 13, 2024.